Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Appropriate medicines: options for pre-exposure prophylaxis (WHO, 2018)

7 July 2022

In March 2016, WHO and UNAIDS jointly convened a technical group of experts in antiretroviral (ARV) pharmacology and HIV pre-exposure prophylaxis (PrEP) clinical research to provide clarifications related to three specific implementation concerns for countries regarding the appropriate use of PrEP drug regimens:

  • possible use of lamivudine (3TC) as an alternative to emtricitabine (FTC) for oral PrEP containing tenofovir disoproxil fumarate (TDF),
  • possible use of TDF alone for oral PrEP, and
  • safety of PrEP during pregnancy and breastfeeding, in terms of both maternal and fetal/newborn outcomes.

The technical consultation reviewed a spectrum of evidence, including animal studies, human pharmacology and randomized clinical trials on PrEP as well as indirect evidence from HIV treatment studies.

Product(s): F/TAF, TDF/xTC

Format(s): External Link

Source(s): WHO

Type: External Link

Visit

Featured Resources

Spreadsheet

2024 Q3 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…
Document

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…
External Link

Initiation and Continued Use of Oral Pre-Exposure Prophylaxis among Pregnant and Postpartum Women in South Africa (PrEP-PP): A demonstration cohort study

This article from The Lancet HIV describes the results of a demonstration study in South Africa, PrEP-PP, to integrate oral PrEP provision into public clinics offering antenatal and postnatal care to pregnant and lactating people.
Document

PURPOSE 1 Summary

This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa and Uganda.
Document

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…
External Link

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled analysis from 72 global studies

This article from Clinical Infectious Diseases reviews 72 prospective studies of daily oral PrEP (TDF/FTC) to evaluate its impact on HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings.
Document

Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (Spanish)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…
External Link

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women

This article from the Journal of the American Medical Association describes the results of a pooled analysis to measure HIV incidence among cisgender women with different adherence trajectories to oral PrEP with TDF/FTC.
External Link

PrEPare_Morocco: A Successful Community-based PrEP Delivery Demonstration Program for Men who Have Sex with Men and Female Sex Workers in Morocco

This article from AIDS Care describes the first PrEP demonstration project in the Middle East/North Africa region, which aimed to assess the feasibility and acceptability of a community-based PrEP program for female sex workers and gay and bisexual men who have sex with men in Morocco’s highest HIV prevalence cities: Agadir, Marrakech, and Casablanca.
Document

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (French)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…